Ceftazidime-Avibactam Versus Colistin for the Treatment of Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Infections: A Multicenter Cohort Study
<b>Purpose:</b> To evaluate the real-world evidence of ceftazidime-avibactam (CAZ-AVI) compared to intravenous colistin for the treatment of multidrug-resistant (MDR) <i>P. aeruginosa</i> infections. <b>Method:</b> This is a multicenter, retrospective cohort study...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-01-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/18/1/108 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832587690991681536 |
|---|---|
| author | Thamer A. Almangour Zakiyah Alkherb Leen Ghonem Mohammed Al Musawa Abdullah Almohaizeie Sara Almuhisen Aminah Alharbi Nader Damfu Doaa Aljefri Jeelan Alghaith Awaly Alfozan Ahlam Alghamdi Ahmad Aljabri Abdullah A. Alhifany Mohammed Alessa Yazed Saleh Alsowaida |
| author_facet | Thamer A. Almangour Zakiyah Alkherb Leen Ghonem Mohammed Al Musawa Abdullah Almohaizeie Sara Almuhisen Aminah Alharbi Nader Damfu Doaa Aljefri Jeelan Alghaith Awaly Alfozan Ahlam Alghamdi Ahmad Aljabri Abdullah A. Alhifany Mohammed Alessa Yazed Saleh Alsowaida |
| author_sort | Thamer A. Almangour |
| collection | DOAJ |
| description | <b>Purpose:</b> To evaluate the real-world evidence of ceftazidime-avibactam (CAZ-AVI) compared to intravenous colistin for the treatment of multidrug-resistant (MDR) <i>P. aeruginosa</i> infections. <b>Method:</b> This is a multicenter, retrospective cohort study conducted in the period between 2017 and 2023 at five institutions for patients who received either CAZ-AVI or colistin-based regimens for treating MDR <i>P. aeruginosa</i> infections. Outcomes were compared using multivariate logistic regression analysis. <b>Result:</b> Among the screened patients, 203 patients were included: 89 in the CAZ-AVI group and 114 in the colistin group. A total of 57% presented with pneumonia, 21% with bacteremia, and 61% were in the intensive care unit. The rate of clinical cure was significantly higher among patients who received CAZ-AVI (67% vs. 50%; OR, 2.07; 95% CI, 1.16–3.68). The rate of in-hospital mortality was numerically lower among patients who received CAZ-AVI (40% vs. 49%; OR, 0.58; 95% CI, 0.33–1.03). The rate of AKI was significantly lower among patients who received CAZ-AVI (15% vs. 43%; OR, 0.23; 95% CI, 0.11–0.45). <b>Conclusion:</b> CAZ-AVI was more effective in treating MDR <i>P. aeruginosa</i> infections and showed a better safety profile compared to colistin. Thus, CAZ-AVI could be a better alternative for treating MDR <i>P. aeruginosa</i> infections. |
| format | Article |
| id | doaj-art-11a398de61e34135ac14941e8374e01a |
| institution | Kabale University |
| issn | 1424-8247 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj-art-11a398de61e34135ac14941e8374e01a2025-01-24T13:45:25ZengMDPI AGPharmaceuticals1424-82472025-01-0118110810.3390/ph18010108Ceftazidime-Avibactam Versus Colistin for the Treatment of Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Infections: A Multicenter Cohort StudyThamer A. Almangour0Zakiyah Alkherb1Leen Ghonem2Mohammed Al Musawa3Abdullah Almohaizeie4Sara Almuhisen5Aminah Alharbi6Nader Damfu7Doaa Aljefri8Jeelan Alghaith9Awaly Alfozan10Ahlam Alghamdi11Ahmad Aljabri12Abdullah A. Alhifany13Mohammed Alessa14Yazed Saleh Alsowaida15Department of Clinical Pharmacy, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi ArabiaClinical Pharmacy Services, King Saud University Medical City, King Saud University, Riyadh 11451, Saudi ArabiaClinical Pharmacy Services, King Saud University Medical City, King Saud University, Riyadh 11451, Saudi ArabiaPharmaceutical Care Division, King Faisal Specialist Hospital & Research Centre, Jeddah 23433, Saudi ArabiaPharmaceutical Care Division, King Faisal Specialist Hospital & Research Centre, Riyadh 12713, Saudi ArabiaPharmacy Services Administration, King Fahad Medical City, Riyadh 12231, Saudi ArabiaPharmaceutical Care Division, King Faisal Specialist Hospital & Research Centre, Jeddah 23433, Saudi ArabiaKing Abdullah International Medical Research Centre, Riyadh 11481, Saudi ArabiaPharmaceutical Care Division, King Faisal Specialist Hospital & Research Centre, Jeddah 23433, Saudi ArabiaPharmaceutical Care Division, King Faisal Specialist Hospital & Research Centre, Riyadh 12713, Saudi ArabiaPharmaceutical Care Division, King Faisal Specialist Hospital & Research Centre, Riyadh 12713, Saudi ArabiaDepartment of Pharmacy Practice, College of Pharmacy, Princess Nourah bint Abdulrahman University, P.O. Box 84428, Riyadh 11671, Saudi ArabiaPharmaceutical Care Department, King Salman bin Abdulaziz Medical City, Madinah 42319, Saudi ArabiaPharmacy Practices Department, College of Pharmacy, Umm Al-Qura University, Makkah 24382, Saudi ArabiaDepartment of Clinical Pharmacy, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi ArabiaDepartment of Clinical Pharmacy, College of Pharmacy, University of Ha’il, P.O. Box 6166, Hail 81442, Saudi Arabia<b>Purpose:</b> To evaluate the real-world evidence of ceftazidime-avibactam (CAZ-AVI) compared to intravenous colistin for the treatment of multidrug-resistant (MDR) <i>P. aeruginosa</i> infections. <b>Method:</b> This is a multicenter, retrospective cohort study conducted in the period between 2017 and 2023 at five institutions for patients who received either CAZ-AVI or colistin-based regimens for treating MDR <i>P. aeruginosa</i> infections. Outcomes were compared using multivariate logistic regression analysis. <b>Result:</b> Among the screened patients, 203 patients were included: 89 in the CAZ-AVI group and 114 in the colistin group. A total of 57% presented with pneumonia, 21% with bacteremia, and 61% were in the intensive care unit. The rate of clinical cure was significantly higher among patients who received CAZ-AVI (67% vs. 50%; OR, 2.07; 95% CI, 1.16–3.68). The rate of in-hospital mortality was numerically lower among patients who received CAZ-AVI (40% vs. 49%; OR, 0.58; 95% CI, 0.33–1.03). The rate of AKI was significantly lower among patients who received CAZ-AVI (15% vs. 43%; OR, 0.23; 95% CI, 0.11–0.45). <b>Conclusion:</b> CAZ-AVI was more effective in treating MDR <i>P. aeruginosa</i> infections and showed a better safety profile compared to colistin. Thus, CAZ-AVI could be a better alternative for treating MDR <i>P. aeruginosa</i> infections.https://www.mdpi.com/1424-8247/18/1/108<i>P. aeruginosa</i>multidrug-resistantceftazidime-avibactamcolistin |
| spellingShingle | Thamer A. Almangour Zakiyah Alkherb Leen Ghonem Mohammed Al Musawa Abdullah Almohaizeie Sara Almuhisen Aminah Alharbi Nader Damfu Doaa Aljefri Jeelan Alghaith Awaly Alfozan Ahlam Alghamdi Ahmad Aljabri Abdullah A. Alhifany Mohammed Alessa Yazed Saleh Alsowaida Ceftazidime-Avibactam Versus Colistin for the Treatment of Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Infections: A Multicenter Cohort Study Pharmaceuticals <i>P. aeruginosa</i> multidrug-resistant ceftazidime-avibactam colistin |
| title | Ceftazidime-Avibactam Versus Colistin for the Treatment of Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Infections: A Multicenter Cohort Study |
| title_full | Ceftazidime-Avibactam Versus Colistin for the Treatment of Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Infections: A Multicenter Cohort Study |
| title_fullStr | Ceftazidime-Avibactam Versus Colistin for the Treatment of Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Infections: A Multicenter Cohort Study |
| title_full_unstemmed | Ceftazidime-Avibactam Versus Colistin for the Treatment of Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Infections: A Multicenter Cohort Study |
| title_short | Ceftazidime-Avibactam Versus Colistin for the Treatment of Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Infections: A Multicenter Cohort Study |
| title_sort | ceftazidime avibactam versus colistin for the treatment of multidrug resistant i pseudomonas aeruginosa i infections a multicenter cohort study |
| topic | <i>P. aeruginosa</i> multidrug-resistant ceftazidime-avibactam colistin |
| url | https://www.mdpi.com/1424-8247/18/1/108 |
| work_keys_str_mv | AT thameraalmangour ceftazidimeavibactamversuscolistinforthetreatmentofmultidrugresistantipseudomonasaeruginosaiinfectionsamulticentercohortstudy AT zakiyahalkherb ceftazidimeavibactamversuscolistinforthetreatmentofmultidrugresistantipseudomonasaeruginosaiinfectionsamulticentercohortstudy AT leenghonem ceftazidimeavibactamversuscolistinforthetreatmentofmultidrugresistantipseudomonasaeruginosaiinfectionsamulticentercohortstudy AT mohammedalmusawa ceftazidimeavibactamversuscolistinforthetreatmentofmultidrugresistantipseudomonasaeruginosaiinfectionsamulticentercohortstudy AT abdullahalmohaizeie ceftazidimeavibactamversuscolistinforthetreatmentofmultidrugresistantipseudomonasaeruginosaiinfectionsamulticentercohortstudy AT saraalmuhisen ceftazidimeavibactamversuscolistinforthetreatmentofmultidrugresistantipseudomonasaeruginosaiinfectionsamulticentercohortstudy AT aminahalharbi ceftazidimeavibactamversuscolistinforthetreatmentofmultidrugresistantipseudomonasaeruginosaiinfectionsamulticentercohortstudy AT naderdamfu ceftazidimeavibactamversuscolistinforthetreatmentofmultidrugresistantipseudomonasaeruginosaiinfectionsamulticentercohortstudy AT doaaaljefri ceftazidimeavibactamversuscolistinforthetreatmentofmultidrugresistantipseudomonasaeruginosaiinfectionsamulticentercohortstudy AT jeelanalghaith ceftazidimeavibactamversuscolistinforthetreatmentofmultidrugresistantipseudomonasaeruginosaiinfectionsamulticentercohortstudy AT awalyalfozan ceftazidimeavibactamversuscolistinforthetreatmentofmultidrugresistantipseudomonasaeruginosaiinfectionsamulticentercohortstudy AT ahlamalghamdi ceftazidimeavibactamversuscolistinforthetreatmentofmultidrugresistantipseudomonasaeruginosaiinfectionsamulticentercohortstudy AT ahmadaljabri ceftazidimeavibactamversuscolistinforthetreatmentofmultidrugresistantipseudomonasaeruginosaiinfectionsamulticentercohortstudy AT abdullahaalhifany ceftazidimeavibactamversuscolistinforthetreatmentofmultidrugresistantipseudomonasaeruginosaiinfectionsamulticentercohortstudy AT mohammedalessa ceftazidimeavibactamversuscolistinforthetreatmentofmultidrugresistantipseudomonasaeruginosaiinfectionsamulticentercohortstudy AT yazedsalehalsowaida ceftazidimeavibactamversuscolistinforthetreatmentofmultidrugresistantipseudomonasaeruginosaiinfectionsamulticentercohortstudy |